Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and inflammatory diseases. The company's pipeline features several drug candidates. OD-001 is an oral small molecule inhibitor of receptor-interacting protein kinase 2, currently in a Phase 2a trial for the treatment of ulcerative colitis. OD-002 is an oral small molecule SLC15A4 inhibitor, designed to block the activation of interferon regulatory factor 5 (IRF5) which mediates pathogenic inflammatory responses driven by TLR7/8/9. Another candidate, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on Treg cells. The pipeline also includes a TSLP/IL-33 bispecific antagonist, an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor, and a small molecule inhibitor of IRF5. Odyssey Therapeutics, Inc. was incorporated in 2021 and is headquartered in Boston, Massachusetts.